Myasthenic Syndromes, Congenital
2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program1
1
amifampridine phosphatePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Catalyst Pharmaceuticalsamifampridine phosphate
Clinical Trials (1)
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Start: Jan 2016Est. completion: Oct 2019
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space